Adaptive Biotechnologies Analyst Price Targets

Wall Street analyst price targets and consensus rating for Adaptive Biotechnologies (ADPT).

Price Target Range — 13 Quarters

Analyst Consensus — 7 Analysts

7Buy

Consensus RatingBuy# Analysts7Avg. Consensus PT$24Upside to Avg. PT-7.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 13, 2026	TD Cowen	Dan Brennan	PT Raise	Buy	$28→$32
Oct 13, 2026	Morgan Stanley	Tejas Savant	PT Raise	Equal-Weight	$22→$27
Oct 1, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$25→$32
Sep 29, 2026	Goldman Sachs	Evie Koslosky	Initiate	Buy	$35
Sep 22, 2026	BTIG	Mark Massaro	PT Raise	Buy	$25→$34
Aug 4, 2026	Piper Sandler	David Westenberg	PT Raise	Overweight	$20→$28
Jul 30, 2026	Morgan Stanley	Tejas Savant	PT Raise	Equal-Weight	$20→$22
Jul 30, 2026	TD Cowen	Dan Brennan	PT Raise	Buy	$25→$28
Jul 30, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$22→$25
Jul 30, 2026	BTIG	Mark Massaro	PT Raise	Buy	$24→$25
Jul 9, 2026	Morgan Stanley	Tejas Savant	PT Raise	Equal-Weight	$18→$20
Jun 29, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$21→$22
Jun 17, 2026	BTIG	Mark Massaro	Maintained	Buy	$22
May 12, 2026	Morgan Stanley	Tejas Savant	PT Cut	Equal-Weight	$21→$18
May 6, 2026	JP Morgan	Sebastian Sandler	PT Cut	Overweight	$21→$19
May 6, 2026	TD Cowen	Dan Brennan	PT Raise	Buy	$19→$21
May 6, 2026	Guggenheim	Subbu Nambi	Maintained	Buy	$21
May 6, 2026	BTIG	Mark Massaro	Maintained	Buy	$22
Feb 6, 2026	JP Morgan	Sebastian Sandler	PT Raise	Overweight	$20→$21
Feb 6, 2026	BTIG	Mark Massaro	PT Raise	Buy	$21→$22

Analyst Ratings News

PRO
TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32

TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $28 to $32.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $27

Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $22 to $27.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32

Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $32.

Benzinga Newsdesk

PRO
Goldman Sachs Initiates Coverage On Adaptive Biotechnologies with Buy Rating, Announces Price Target of $35

Goldman Sachs analyst Evie Koslosky initiates coverage on Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy rating and announces Price Target of $35.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34

BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $34.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $27.5

Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the price target from $20 to $27.5.

Benzinga Newsdesk

Adaptive Biotechnologies Corp

Adaptive Biotechnologies Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32

PRO
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $27

PRO
Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32

PRO
Goldman Sachs Initiates Coverage On Adaptive Biotechnologies with Buy Rating, Announces Price Target of $35

PRO
BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34

PRO
Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $27.5

People Also Watch

People Also Watch

Adaptive Biotechnologies Corp

Adaptive Biotechnologies Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROTD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32

PROMorgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $27

PROGuggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32

PROGoldman Sachs Initiates Coverage On Adaptive Biotechnologies with Buy Rating, Announces Price Target of $35

PROBTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34

PROPiper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $27.5

People Also Watch

People Also Watch

PRO
TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32

PRO
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $27

PRO
Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32

PRO
Goldman Sachs Initiates Coverage On Adaptive Biotechnologies with Buy Rating, Announces Price Target of $35

PRO
BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34

PRO
Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $27.5